In India, a crisis happened in late 2025 with respect to a cough syrup, which led to fatal cases of many children, and in no time, the news spread across and encouraged swift action, including banning the cough syrup, shutting the manufacturing facility, and imposing legal action against the organization. Hope you realize which factor played a crucial role in recognizing the adverse event (AE) in that particular scenario. It is social media platforms like Facebook and Twitter (X) that took the center stage in reporting and spreading awareness about that adverse event.
Considering the above scenario, Adverse event (AE) detection is no longer a passive or paper-driven aspect. It is undergoing a significant transformation, with optimal use of social media channels, especially when listening to real-world patient experiences. Social media can surface earlier signals, track qualitative patient narratives, and unreported reactions. It evidently showcases that adverse event information appears online way faster than it is captured in spontaneous reporting systems. Though it is restricted to specific products and scenarios, the capturing time is faster in social media. In addition, social media adverse event reporting provides context (lifestyle, comorbidities, and behavioural patterns) that individual case safety reports (ICSRs) rarely or sometimes capture.
How different are Traditional PV Reporting and Social Media Reporting?
| Traditional Pharmacovigilance Reporting | Social Media Reporting |
| Relies on Spontaneous Reports
Clinical Trials, Literature, Registries |
Relies on Patient Forums, Health Communities, Patient Reviews |
| Offers challenges of under-reporting | Offers a continuous and real stream of user-engaged and generated scenarios (symptoms, side effects, alteration in medication switches |
| There might be time lag in event occurrence to event recognition | High chances of quick event recognition and making it viral within no time |
After discussing the points, social media as a platform seems more promising for detecting adverse events. No matter if it is a new or unexpected AE, it captures the product’s off-label use and presents an opportunity to understand how it can impact quality of life. But, like any other reporting system, social media too has its own limitations and is considered a complementary signal rather than an established pharmacovigilance (PV) signal-detection system.
The limitations of social media in adverse event reporting can be:
- data quality
- ethical reporting and
- regulatory justification
The workflow of signal generation on social media
As mentioned above, there is little room for structured ICSRs at this time. With the advent of social media, organizations and their PV teams have been forced to rethink how they generate signals. They are integrating social listening into their digital ecosystem instead of waiting for structured ICSRs. They are up for safety intelligence workflows like:
- Integrating APIs or web‑scraping tools that collect posts mentioning brand names and common lay synonyms. It filters and removes marketing content and irrelevant chats.
- Integrating Natural language processing (NLP) models which detect potential drug, indication, and reaction mentions. NLP handles misspellings, slang, emojis, and implicit language, making the AE recognition easy.
- Integrating Machine‑learning models to evaluate how likely a post resembles and establishes a genuine drug–event relationship. This association and scoring can sometimes lead to mining or sentiment analysis, which helps prioritise strong candidates.
- Tracking the potential posts with an identifiable patient, a valid reporter, and a drug name can easily establish a valid ICSR. So that follow-up or documentation can be easily generated, in accordance with GVP Module VI.
Overall, the role of social media in PV signal detection may be ahead of that of traditional data sources in identifying specific safety concerns, especially for the most-discussed drugs or vaccines. How to use it? What compliance best practices can be referred to while doing so? What responsibilities should an MAH hold up as per the EU GVP Module VI? If these are the questions you are wondering about, reach out to a Regulatory expert.